Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 16456 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain!Just think of all thetrillions and trillions of neuronsthateach daybecause there areNOeffective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group. My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html
Wednesday, August 29, 2018
Poststroke Depression Biomarkers: A Narrative Review
If you got survivors 100% recovered you wouldn't have to tackle this secondary problem of depression. Focus on the primary problem and you wouldn't have all these secondary problems to deal with. That is where exact stroke protocols tied to specific objective damage diagnosis comes in. If your doctor and stroke hospital can't see that they need to be fired. https://www.frontiersin.org/articles/10.3389/fneur.2018.00577/full?
State Institution “Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine, ” Zaporizhzhia, Ukraine
Poststroke depression (PSD) is the most prevalent psychiatric
disorder after stroke, which is independently correlated with negative
clinical outcome. The identification of specific biomarkers could help
to increase the sensitivity of PSD diagnosis and elucidate its
pathophysiological mechanisms. The aim of current study was to review
and summarize literature exploring potential biomarkers for PSD
diagnosis. The PubMed database was searched for papers published in
English from October 1977 to December 2017, 90 of which met inclusion
criteria for clinical studies related to PSD biomarkers. PSD biomarkers
were subdivided into neuroimaging, molecular, and neurophysiological.
Some of them could be recommended to support PSD diagnosing. According
to the data, lesions affecting the frontal-subcortical circles of mood
regulation (prefrontal cortex, basal nuclei, and thalamus) predominantly
in the left hemisphere can be considered as neuroimaging markers and
predictors for PSD for at least 1 year after stroke. Additional pontine
and lobar cerebral microbleeds in acute stroke patients, as well as
severe microvascular lesions of the brain, increase the likelihood of
PSD. The following molecular candidates can help to differentiate PSD
patients from non-depressed stroke subjects: decreased serum BDNF
concentrations; increased early markers of inflammation
(high-sensitivity C-reactive protein, ferritin, neopterin, and
glutamate), serum pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18,
IFN-γ), as well as pro-inflammatory/anti-inflammatory ratios
(TNF-α/IL-10, IL-1β/IL-10, IL-6/IL-10, IL-18/IL-10, IFN-γ/IL-10);
lowered complement expression; decreased serum vitamin D levels;
hypercortisolemia and blunted cortisol awakening response; S/S 5-HTTLPR,
STin2 9/12, and 12/12 genotypes of the serotonin transporter gene
SLC6A4, 5-HTR2a 1438 A/A, and BDNF met/met genotypes; higher SLC6A4
promoter and BDNF promoter methylation status. Neurophysiological
markers of PSD, that reflect a violation of perception and cognitive
processing, are the elongation of the latency of N200, P300, and N400,
as well as the decrease in the P300 and N400 amplitude of the
event-related potentials. The selected panel of biomarkers may be useful
for paraclinical underpinning of PSD diagnosis, clarifying various
aspects of its multifactorial pathogenesis, optimizing therapeutic
interventions, and assessing treatment effectiveness.
Poststroke depression (PSD) is the most prevalent
psychiatric disorder after stroke, which affects nearly one-third of the
survivors during first 5 years after disease onset (1–3).
The diagnosis of PSD includes the following characteristics: (1)
presence of major/minor depressive episode according to DSM-III-IV-5 or
other valid approaches; (2) evidence of stroke from history, physical
examination, and/or neuroimaging data; and (3) onset of PSD is
temporally related to the stroke (3).
Several epidemiological findings have demonstrated that PSD is
independently linked to negative clinical outcomes, such as
significantly longer hospitalization; more severe functional disability (3–6); profound diminutions in physical, psycho-social, cognitive, and eco-social domains of quality of life (3, 7); unsatisfactory results of poststroke rehabilitation (8); elevated rates of mortality (3, 9–11); higher risks of recurrent stroke at 1 year (12); as well as considerable strain for caregivers (13). Data mentioned above highlight the importance of identifying PSD among stroke survivors.
The detection of depressive symptoms at early stroke
stages and recognition subjects at risk for PSD diagnosis remains
challenging. Clinical measures currently used to assess PSD, especially
in the acute poststroke patients, may lack the specificity necessary to
detect symptoms (14, 15).
From this point of view, the identification of specific biomarkers
might help to increase the sensitivity of PSD diagnosis. Moreover, it
could be helpful for elucidating the pathophysiological mechanisms of
PSD and ultimately lead to choosing specific targeted treatment (16).
Thus, we aimed to review and summarize the literature exploring potential biomarkers for PSD diagnosis.